UBS O'Connor’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

UBS O'Connor’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-151,796	Closed	-$2.39M	–	653
2024 Q1	$2.39M	Buy	151,796 +33,876	+29%	+$521K	0.07%	149
2023 Q4	$1.9M	Sell	117,920 -35,817	-23%	-$457K	0.06%	178
2023 Q3	$1.96M	Buy	153,737 +77,000	+100%	+$1.06M	0.03%	248
2023 Q2	$1.08M	Buy	76,737 +18,042	+31%	+$258K	0.02%	376
2023 Q1	$907K	Buy	58,695 +11,195	+24%	+$187K	0.02%	423
2022 Q4	$779K	Buy	47,500 +37,500	+375%	+$610K	0.01%	589
2022 Q3	$185K	Buy	+10,000	New	+$157K	﹤0.01%	846

Other funds holding DCPH

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

UBS O'Connor's DCPH Position: Q2 2024 in Review

UBS O'Connor sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 151,796 shares — an estimated $2.39M sold.

UBS O'Connor first reported a position in DCPH in Q3 2022 and held it in 7 quarters. The position peaked at $2.39M in Q1 2024. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

UBS O'Connor reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
UBS O'Connor sold 151,796 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $2.39M.
UBS O'Connor first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 7 quarters.
UBS O'Connor's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $2.39M in Q1 2024.
1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.